Avacincaptad pegol
Highest phase reached
Phase 3
Drug type
Oligonucleotide
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Oligonucleotide
- Drug name
- Avacincaptad pegol
- arc 1905 free acid
- ARC-1905 FREE ACID
- avacincaptad pegol
- Avacincaptad pegol
- avacincaptad pegol [INN]
- Avacincaptad pegol [MI]
- Avacincaptad pegol [WHO-DD]
- avacincaptad pegol inn
- avacincaptad pegol mi
- avacincaptad pegol who dd
- poly oxy 1 2 ethanediyl α hydro ω methoxy 5 ether with rna 2 deoxy 2 fluoro c gm 2 deoxy 2 fluoro c 2 deoxy 2 fluoro c g 2 deoxy 2 fluoro c gm gm 2 deoxy 2 fluoro u 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u 2 deoxy 2 fluoro c am gm gm 2 deoxy 2 fluoro c g 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u gm am gm 2 deoxy 2 fluoro u 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u gm am gm 2 deoxy 2 fluoro u 2 deoxy 2 fluoro u 2 deoxy 2 fluoro u a 2 deoxy 2 fluoro c 2 deoxy 2 fluoro c 2 deoxy 2 fluoro u gm 2 deoxy 2 fluoro c gm 3 3 dt 5 6 2 3 dihydroxypropoxy carbonyl amino hexyl hydrogen phosphate 2 1
- Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, 5′-ether with RNA ((2′-deoxy-2′-fluoro)C-Gm-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-Gm-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-Am-Gm-Gm-(2′-deoxy-2′-fluoro)C-G-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-Gm-(2′-deoxy-2′-fluoro)C-Gm-(3′→3′)-dT) 5′-[6-[[(2,3-dihydroxypropoxy)carbonyl]amino]hexyl hydrogen phosphate] (2:1)
- zimura
- Zimura
- ATC classification codes
- S01XA32
Sources for recorded values
- CAS registry numbers
- 1613641-69-2
- ChEMBL ID
- CHEMBL6068573
- RxNorm IDs (RxCUI)
- 2645108
- FDA ingredient codes (UNII)
- TT0V5JLG5B
- Status
- application_withdrawn
- Status date
- 24 Oct 2024
- Approved indications
- Indicated for the treatment of adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- Product number
- EMEA/H/C/006153
- Authorisation holder
- Astellas Pharma Europe B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Geographic Atrophy
- Macular Degeneration
European medicines record
- Patents
- 0
- Designations
- 5
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- avacincaptad pegol
- Type
- Nucleic acid
- Drug name stem
- peg-
- Approval recorded by Guide to Pharmacology
- Yes
- Condition
- Macular Degeneration
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001365
- Subject identifier
- D008268
- Condition
- Eye Diseases
- Highest recorded phase
- -1
- Condition identifier
- EFO:0003966
- Subject identifier
- D005128
- Condition
- Geographic Atrophy
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001492
- Subject identifier
- D057092
- Condition identifier
- EFO_0001365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003966
- Condition identifier
- EFO_0004683
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009606
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001492
- Condition identifier
- EFO_1001492
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003004
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005150
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005328
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005417
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0100114
- Condition identifier
- MONDO_0100114
- Highest recorded phase
- 2
- Event
- intercepted product preparation error
- Reports
- 15
- Reporting signal score
- 70.1488
- Event
- needle issue
- Reports
- 18
- Reporting signal score
- 76.1189
- NCT03364153
- NCT04435366
- NCT05536297
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (13)
- A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
- A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
- A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
- A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
- A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
- ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
- Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
- Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
- Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
- ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
- ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)
- Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
In development for (4)
- Age-related macular degeneration Phase 2
- Eye disorder
- Macular degeneration Phase 3
- Wet macular degeneration Phase 2
Other linked conditions (1)
- Dry age related macular degeneration